A non-profit manufacturer for shortage-prone generic chemotherapy
Cisplatin and carboplatin cost a few dollars a dose yet ran short across the US in 2023 because too few makers found them worth producing; a non-profit maker with long-term hospital contracts would keep them on the shelf.
Overview
Civica Rx showed that a hospital-owned non-profit can manufacture and stock essential generics under long-term, fixed-price contracts, stabilising supply of sterile injectables. Oncology generics (platinums, fluorouracil, methotrexate, vincristine) are cheap, old and shortage-prone because thin margins push manufacturers out. A dedicated oncology line, funded by hospital consortia and philanthropy, would hold safety stock and dual-source active ingredients. The saving is not the drug price but the avoided cost of substitution, delay and dearer alternatives when a shortage hits.
- Prices and value · New cancer drugs routinely cost over $150,000 a year, often for months of benefit. Systems cannot afford them and patients go bankrupt.
- Most of the world has almost no cancer care · Seven in ten cancer deaths happen in low- and middle-income countries, where radiotherapy, pathology, surgery and drugs are scarce.
Pages like this
not linked directly; found by shared links- IdeaA non-profit manufacturer for generic cancer drugs in chronic shortage
Shares Platinum agents, Carboplatin, Prices and value, Most of the world has almost no cancer care.
- TechnologyGeneric oncology drug supply and shortage mitigation
Shares Civica Rx, Platinum agents, Cytotoxic chemotherapy.
- IdeaPublic-option manufacturing for essential generic cancer drugs in shortage
Shares Platinum agents, Carboplatin, Prices and value, Most of the world has almost no cancer care.
- IdeaA strategic reserve of essential generic cancer drugs to end recurring shortages
Shares Platinum agents, Carboplatin, Most of the world has almost no cancer care.
- IdeaPooled international procurement of essential adult cancer medicines
Shares Carboplatin, Prices and value, Most of the world has almost no cancer care.
- IdeaChoose regimens by infusion-chair hours, not just efficacy, where chairs are the constraint
Shares Carboplatin, Most of the world has almost no cancer care, Cytotoxic chemotherapy.
- CompanyCipla
Shares Prices and value, Most of the world has almost no cancer care, Cytotoxic chemotherapy.
- PersonAimery de Gramont
Shares Platinum agents, Cytotoxic chemotherapy.